<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10</volume><submitter>Po' C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Moyamoya is a rare progressive cerebral arteriopathy, occurring as an isolated phenomenon (moyamoya disease, MMD) or associated with other conditions (moyamoya syndrome, MMS), responsible for 6-10% of all childhood strokes and transient ischemic attacks (TIAs).&lt;h4>Methods&lt;/h4>We conducted a retrospective multicenter study on pediatric-onset MMD/MMS in Italy in order to characterize disease presentation, course, management, neuroradiology, and outcome in a European country.&lt;h4>Results&lt;/h4>A total of 65 patients (34/65 women) with MMD (27/65) or MMS (38/65) were included. About 18% (12/65) of patients were asymptomatic and diagnosed incidentally during investigations performed for an underlying condition (incMMS), whereas 82% (53/65) of patients with MMD or MMS were diagno</pubmed_abstract><journal>Frontiers in pediatrics</journal><pagination>892445</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9120837</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pediatric Moyamoya Disease and Syndrome in Italy: A Multicenter Cohort.</pubmed_title><pmcid>PMC9120837</pmcid><pubmed_authors>Ragazzi P</pubmed_authors><pubmed_authors>Giordano L</pubmed_authors><pubmed_authors>Morini G</pubmed_authors><pubmed_authors>Scelsa B</pubmed_authors><pubmed_authors>Sanfilippo G</pubmed_authors><pubmed_authors>Lafe E</pubmed_authors><pubmed_authors>Colombatti R</pubmed_authors><pubmed_authors>Thyrion FZ</pubmed_authors><pubmed_authors>Po' C</pubmed_authors><pubmed_authors>Martelli P</pubmed_authors><pubmed_authors>Mirone G</pubmed_authors><pubmed_authors>Polonara G</pubmed_authors><pubmed_authors>Raviglione F</pubmed_authors><pubmed_authors>Toni F</pubmed_authors><pubmed_authors>Zedde M</pubmed_authors><pubmed_authors>Marras CE</pubmed_authors><pubmed_authors>Cirillo L</pubmed_authors><pubmed_authors>Di Rosa G</pubmed_authors><pubmed_authors>Cordelli DM</pubmed_authors><pubmed_authors>Nicita F</pubmed_authors><pubmed_authors>Cosi A</pubmed_authors><pubmed_authors>Sartori S</pubmed_authors><pubmed_authors>Foiadelli T</pubmed_authors><pubmed_authors>Manara R</pubmed_authors><pubmed_authors>Toldo I</pubmed_authors><pubmed_authors>Pruna D</pubmed_authors><pubmed_authors>Spalice A</pubmed_authors><pubmed_authors>Lanterna LA</pubmed_authors><pubmed_authors>Sainati L</pubmed_authors><pubmed_authors>Baro V</pubmed_authors><pubmed_authors>Operto FF</pubmed_authors><pubmed_authors>Suppiej A</pubmed_authors><pubmed_authors>Carai A</pubmed_authors><pubmed_authors>Nosadini M</pubmed_authors><pubmed_authors>De Carlo L</pubmed_authors><pubmed_authors>Azzolina D</pubmed_authors><pubmed_authors>Bova SM</pubmed_authors><pubmed_authors>Rollo M</pubmed_authors><pubmed_authors>Pascarella R</pubmed_authors><pubmed_authors>Cesaroni E</pubmed_authors><pubmed_authors>Esposito G</pubmed_authors><pubmed_authors>Frigo AC</pubmed_authors><pubmed_authors>Grazian L</pubmed_authors><pubmed_authors>Savasta S</pubmed_authors><pubmed_authors>Campa S</pubmed_authors><pubmed_authors>Accorsi P</pubmed_authors><pubmed_authors>Iodice A</pubmed_authors><pubmed_authors>Cicala D</pubmed_authors><pubmed_authors>Greco F</pubmed_authors><pubmed_authors>Striano P</pubmed_authors><pubmed_authors>Agostini M</pubmed_authors><pubmed_authors>Skabar A</pubmed_authors><pubmed_authors>Rosati A</pubmed_authors><pubmed_authors>Causin F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pediatric Moyamoya Disease and Syndrome in Italy: A Multicenter Cohort.</name><description>&lt;h4>Background&lt;/h4>Moyamoya is a rare progressive cerebral arteriopathy, occurring as an isolated phenomenon (moyamoya disease, MMD) or associated with other conditions (moyamoya syndrome, MMS), responsible for 6-10% of all childhood strokes and transient ischemic attacks (TIAs).&lt;h4>Methods&lt;/h4>We conducted a retrospective multicenter study on pediatric-onset MMD/MMS in Italy in order to characterize disease presentation, course, management, neuroradiology, and outcome in a European country.&lt;h4>Results&lt;/h4>A total of 65 patients (34/65 women) with MMD (27/65) or MMS (38/65) were included. About 18% (12/65) of patients were asymptomatic and diagnosed incidentally during investigations performed for an underlying condition (incMMS), whereas 82% (53/65) of patients with MMD or MMS were diagno</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-05-29T19:23:07.706Z</modification><creation>2025-05-29T19:23:07.706Z</creation></dates><accession>S-EPMC9120837</accession><cross_references><pubmed>35601411</pubmed><doi>10.3389/fped.2022.892445</doi></cross_references></HashMap>